Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Theranostics|May 17, 2021
Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancerCong Zhang, Zhuowen Yang, Peng Zhou, et al.
Ebiomedicine|September 19, 2020
Endothelial damage and a thin intercellular fibrin network promote haemorrhage in acute promyelocytic leukaemiaChunxu Wang, Muxin Yu, Peng Zhou, et al.
Scientific Reports|March 24, 2026
Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patientsAndrew B Nixon, Fábio C P Navarro, Katherine I Zhou, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2019
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)Jeffrey Melson Clarke, Gerard C Blobe, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor ImmunotherapyMark J A Schoonderwoerd, Maaike F M Koops, Ricardo A Angela, et al.
The Oncologist|April 8, 2021
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)Toni K Choueiri, Yousef Zakharia, Sumanta Pal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)Andrew B Nixon, Alexander B Sibley, Yingmiao Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II StudyErika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
Molecular Cancer Therapeutics|August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, et al.
Pageof 6